MGMikel Garcia-Marcos

Mikel Garcia-Marcos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mikel Garcia-Marcos has a total of 225 co-authors. Here are the top co-authors by number of shared publications:

  • Marcin Maziarz

    Department of Biochemistry & Cell Biology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA

    16 shared publications
  • Arthur Marivin

    Department of Biochemistry, Boston University School of Medicine, Boston, United States

    14 shared publications
  • Pradipta Ghosh

    Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, USA

    12 shared publications
  • Alex Luebbers

    Department of Biochemistry and Cell Biology, Chobanian and Avedisian School of Medicine, Boston University, Boston, MA, USA

    11 shared publications
  • Anthony Leyme

    Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA

    10 shared publications
  • Vincent DiGiacomo

    Department of Biochemistry & Cell Biology, Boston University, Chobanian & Avedisian School of Medicine, Boston, MA 02118

    10 shared publications

Latest Publications

  • The Gα-interacting protein RGS4 in dorsal root ganglia maintains molecular and behavioral maladaptations in murine pain models

    by Randal A. Serafini, Bruno Giotti, Alex Luebbers, Kerri D. Pryce, Ilinca M. Giosan, Madden J. Tuffy, Jeffrey Zimering, Aarthi Ramakrishan, Donghoon Lee, Ekaterina Kintsurashvili, et al.

    Regulator of G protein signaling 4 (RGS4) is a Gα subunit–interacting protein that modulates the functional responses of various G protein–coupled receptors (GPCRs) and that is present in several components of the nociceptive circuitry. Here, we found that RGS4 in lumbar dorsal root ganglia (DRGs) is required for the maintenance of chronic pain states in mice. Rgs4 knockout in Mrgprd + nonpeptidergic C-fibers was sufficient to attenuate sensory hypersensitivity in several acute and chronic injury models without affecting acute nociceptive responses. Single-nucleus RNA sequencing in ipsilateral lumbar DRGs from mice with prolonged peripheral nerve injury identified cell subset–specific gene expression changes in Rgs4 knockout mice after recovery from mechanical hypersensitivity, including Gabbr2 , which encodes the GABA B receptor, in Mrgprd + fibers. RGS4 competed with Gα i -interacting protein (GINIP) to modulate GABA B receptor signaling, which suppresses neuronal excitability. Analysis of genetically modified mice suggested that imbalances in the interplay between RGS4 and GINIP contribute to the maintenance of sensory hypersensitivity and chronic pain states. Overall, our study reveals critical G protein–modulatory pathways in the DRG that promote the maintenance of sensory hypersensitivity in chronic pain models.

  • Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy

    by Hao Zhang, Rabindra V. Shivnaraine, Lu Ren, Phung N. Thai, Remi Janicot, Wenjuan Zhu, Rihua Huang, Dirk H. Siepe, Chengyi Tu, Wenqiang Liu, et al.

    Cardiac fibrosis independently predicts adverse outcomes in heart failure (HF), yet no Food and Drug Administration–approved therapy directly targets fibrotic remodeling in the heart. To address this unmet clinical need, we used a multidimensional drug discovery pipeline centered on a human induced pluripotent stem cell (iPSC)–based platform. Through high-throughput screening, we identified CGS15943 (CGS) as the lead antifibrotic compound and validated its activity in human cardiac fibroblasts, three-dimensional engineered heart tissues, and animal models of HF. Mechanistic studies revealed an atypical adenosine receptor (AR)–dependent signaling pathway in which AR subtypes converge on Gβγ (the βγ subunits of heterotrimeric GTP-binding proteins) to activate phosphoinositide 3-kinase (PI3K)–AKT and yes-associated protein (YAP). CGS suppressed this signaling axis, thereby reducing fibrotic gene expression and fibroblast activation. These findings establish AR-driven Gβγ signaling as a potential therapeutic target for cardiac fibrosis.


  • Open Access

    Oncogenic Gα signaling requires AP-3-dependent recruitment to the endolysosomal compartment

    by Megha Shettigar, Salomé Moulière, Larissa Isenegger, Alexander L. DeVine, Cécile Gstalder, Vidyasagar Koduri, John G. Doench, Bruce Ksander, Mikel Garcia-Marcos, William G. Kaelin, et al.

    G protein–coupled receptors (GPCRs) constitute the largest superfamily of cell-surface receptors, yet the spatial constraints governing their signaling remain poorly defined. Here, we demonstrate that Gα, an essential downstream component of GPCR signaling, undergoes a spatial shift from the plasma membrane to the endolysosomal compartment upon its constitutive activation. Using a genome-wide CRISPR screen, we identify the adaptor protein AP-3 as the essential mediator of this trafficking event. Loss of AP-3-dependent recruitment impairs Gα-driven signaling and proliferation in uveal melanoma cells harboring oncogenic Gα mutations. We further identify a highly evolutionarily conserved AP-3 binding motif in all Gα proteins, present from yeast to humans. Disrupting this site causes Gα mislocalization and potently suppresses tumor growth and metastasis in vivo. Conversely, tethering Gα to the endolysosomal membrane is sufficient to rescue oncogenic signaling. Our findings reveal that endolysosomal recruitment is a fundamental, conserved requirement for Gα activity, uncovering a spatial vulnerability that may be exploited to target dysregulated G-protein signaling in human disease.


  • Inhibitory probes for spatiotemporal analysis of Gαs protein signaling

    by Jingyi Zhao, Alex Luebbers, Sofya Savransky, Ting-Yu Lin, Nan Cheng, Abigail Wilcox, Remi Janicot, Elena Green, Akshay Sharma, Marcin Maziarz, et al.

    Gαs serves as the prototypical signal transducer for G-protein-coupled receptors (GPCRs) and is the heterotrimeric G protein most frequently mutated in cancer. The classical view of the plasma membrane as the only cellular location where GPCR signal transduction occurs has been challenged by evidence suggesting that Gs also signals from intracellular compartments. However, progress on this topic has stalled because of insufficient approaches with adequate spatiotemporal resolution. Here we describe genetically encoded probes and cell-penetrating compounds that block the effector-binding site of active Gαs in cells to prevent signal propagation at discrete subcellular locations, at user-specified times and across diverse experimental conditions. Using these tools, we show direct evidence of Gαs-mediated signaling on intracellular organelles, unique spatiotemporal features of signaling by Gαs oncomutants and specific regulation of physiologically relevant responses in cardiac or immune cells. These findings pave the way to harnessing the spatiotemporal modulation of Gs signaling and its untapped therapeutic potential.


  • A sensitive biosensor of endogenous Gα i activity enables the accurate characterization of endogenous GPCR agonist responses

    by Alex Luebbers, Remi Janicot, Jingyi Zhao, Clementine E. Philibert, Mikel Garcia-Marcos

    The activation of heterotrimeric G proteins (Gαβγ) by G protein–coupled receptors (GPCRs) is a mechanism broadly used by eukaryotes to transduce signals across the plasma membrane and a target for many clinical drugs. Many optical biosensors commonly used for measuring GPCR-stimulated G protein activity rely on exogenously expressed GPCRs and/or G proteins, which compromise readout fidelity. Biosensors that measure endogenous signaling may interfere with the signaling process under investigation or have a limited dynamic range of detection, hindering applicability. Here, we developed an optical BRET-based biosensor, Gα i bONE-GO, that detects endogenous GTP-bound (active) Gα i upon stimulation of endogenous GPCRs more robustly than existing sensors of endogenous activity. Its design leverages the Gα i -binding protein GINIP as a high-affinity and specific detector of Gα i -GTP. We optimized this design to prevent interference with downstream G i -dependent signaling and to enable implementation in different experimental systems having endogenous GPCRs, including adenosine receptors in primary astroglial cells and opioid receptors in cell lines. In a neuronal cell line, Gα i bONE-GO revealed activation profiles indicating that several natural opioid neuropeptides acted as partial agonists, in contrast with their characterization as full agonists using biosensors that depend on exogenously expressed receptors and G proteins. The Gα i bONE-GO biosensor is a direct and sensitive detector of endogenous activation of Gα i proteins by GPCRs in different experimental settings but does not interfere with the subsequent propagation of signaling.


  • Open Access

    Direct detection of endogenous Gαi activity in cells with a sensitive conformational biosensor

    by Alex Luebbers, Remi Janicot, Jingyi Zhao, Clementine E Philibert, Mikel Garcia-Marcos

    Activation of heterotrimeric G-proteins (Gαβγ) by G-protein-coupled receptors (GPCRs) is not only a mechanism broadly used by eukaryotes to transduce signals across the plasma membrane, but also the target for a large fraction of clinical drugs. However, approaches typically used to assess this signaling mechanism by directly measuring G-protein activity, like optical biosensors, suffer from limitations. On one hand, many of these biosensors require expression of exogenous GPCRs and/or G-proteins, compromising readout fidelity. On the other hand, biosensors that measure endogenous signaling may still interfere with the signaling process under investigation or suffer from having a small dynamic range of detection, hindering broad applicability. Here, we developed an optical biosensor that detects the endogenous G-protein active species Gαi-GTP upon stimulation of endogenous GPCRs more robustly than current state-of-the-art sensors for the same purpose. Its design is based on the principle of bystander Bioluminescence Resonance Energy Transfer (BRET) and leverages the Gαi-binding protein named GINIP as a high affinity and specific detector module of the GTP-bound conformation of Gαi. We optimized this design to prevent interference with Gi-dependent signaling (cAMP inhibition) and to enable implementation in different experimental systems with endogenous GPCRs, including neurotransmitter receptors in primary astroglial cells or opioid receptors in cell lines, which revealed opioid neuropeptide-mediated activation profiles different from those observed with other biosensors involving exogenous GPCRs and G-proteins. Overall, we introduce a biosensor that directly and sensitively detects endogenous activation of G-proteins by GPCRs across different experimental settings without interfering with the subsequent propagation of signaling.

  • Get Ready to Sharpen Your Tools: A Short Guide to Heterotrimeric G Protein Activity Biosensors

    by Remi Janicot, Mikel Garcia-Marcos

    G protein-coupled receptors (GPCRs) are the largest class of transmembrane receptors encoded in the human genome, and they initiate cellular responses triggered by a plethora of extracellular stimuli ranging from neurotransmitters or hormones to photons. Upon stimulation, GPCRs activate heterotrimeric G proteins (Gαβγ) in the cytoplasm, which then convey signals to their effectors to elicit cellular responses. Given the broad biological and biomedical relevance of GPCRs and G proteins in physiology and disease, there is great interest in developing and optimizing approaches to measure their signaling activity with high accuracy and across experimental systems pertinent to their functions in cellular communication. This review provides a historical perspective on approaches to measure GPCR-G protein signaling, from quantification of second messengers and other indirect readouts of activity, to biosensors that directly detect the activity of G proteins. The latter is the focus of a more detailed overview of the evolution of design principles for various optical biosensors of G protein activity with different experimental capabilities. We will highlight advantages and limitations of biosensors that detect different G protein activation hallmarks, like dissociation of Gα and Gβγ or nucleotide exchange on Gα, as well as their suitability to detect signaling mediated by endogenous versus exogenous signaling components, or in physiologically-relevant systems like primary cells. Overall, this review intends to provide an assessment of the state-of-the-art for biosensors that directly measure G protein activity to allow readers to make informed decisions on the selection and implementation of currently available tools. Significance Statement G protein activity biosensors have become essential and widespread tools to assess GPCR signaling and pharmacology. Yet, investigators face the challenge of choosing from a growing list of G protein activity biosensors. This review provides an overview of the features and capabilities of different optical biosensor designs for the direct detection of G protein activity in cells, with the aim of facilitating the rational selection of systems that align with the specific scientific questions and needs of investigators.